|
gptkbp:instanceOf
|
gptkb:antibiotic
|
|
gptkbp:affiliatedWith
|
isoxazolyl penicillins
|
|
gptkbp:ATCCode
|
gptkb:J01CF02
|
|
gptkbp:brand
|
gptkb:Cloxapen
gptkb:Orbenin
Tegopen
|
|
gptkbp:CASNumber
|
61-72-3
|
|
gptkbp:chemicalFormula
|
gptkb:C19H18ClN3O5S
|
|
gptkbp:contraindication
|
penicillin allergy
|
|
gptkbp:discoveredBy
|
gptkb:Beecham
|
|
gptkbp:effect
|
Staphylococcus aureus (non-MRSA)
|
|
gptkbp:eliminationHalfLife
|
30 minutes
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cloxacillin
|
|
gptkbp:introducedIn
|
1960s
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits bacterial cell wall synthesis
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
435.88 g/mol
|
|
gptkbp:notEffectiveAgainst
|
gptkb:MRSA
Gram-negative bacteria
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:resistantTo
|
beta-lactamase
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
intravenous
|
|
gptkbp:sideEffect
|
rash
allergic reactions
gastrointestinal upset
liver dysfunction
|
|
gptkbp:spectrumOfActivity
|
narrow spectrum
|
|
gptkbp:usedFor
|
treatment of staphylococcal infections
treatment of skin infections
treatment of respiratory tract infections
treatment of bone and joint infections
treatment of endocarditis
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Hindustan_Antibiotics
|
|
gptkbp:bfsLayer
|
7
|